Conexeu Sciences files Form D for $30,875 equity offering

Conexeu Sciences Inc., a Nevada corporation, filed a Form D notice with the Securities and Exchange Commission for a new exempt securities offering. The issuer is identified as Conexeu Sciences Inc., incorporated in Nevada within the last five years, in 2022.¹ The company's principal place of business is listed at 50 West Liberty Street, Suite 880, Reno, Nevada.¹

The filing marks a new notice, with a date of first sale listed as September 23, 2026.¹ The offering involves equity securities.¹ The company claimed a federal exemption under Rule 506(b).¹

According to the filing's use of proceeds description, the total offering amount represents the aggregate price of 6,500 shares at a deemed price of $4.75 per share, issued as payment for consulting services.¹ Both the total offering amount and total amount sold were reported as $30,875, with $0 remaining to be sold.¹

The filing states that two investors have already invested in the offering.¹ The minimum investment accepted from any outside investor was listed as $0.¹ No sales commissions or finders' fees were reported.¹

The company is categorized under the biotechnology industry group within health care.¹ Its issuer size was listed as "Decline to Disclose" for both revenue range and aggregate net asset value.¹

Related persons named in the filing include David R. Bogart and Miles Harrison, both listed as executive officers and directors, along with several additional executive officers and directors including Aaron Farberg, Stephen D. Inouye, Claudia Chavez-Munoz, Jeff Sharpe, Paul Z. Lorenc, Sebastian Purcell, Brian Pilcher, Andrew Costa, April Burke, and Ana Bastiani-Posner.¹ The notice was signed by Stephen Inouye, the company's CFO, on September 28, 2026.¹